Synthesis, Anticancer Assessment, and Molecular Docking of Novel Chalcone-Thienopyrimidine Derivatives in HepG2 and MCF-7 Cell Lines

Table 3

Preliminary screening of the cytotoxic efficacy of the synthesized chalcone-thienopyrimidine derivatives 3a-g against human liver cancer cell line (HepG2) compared to DMSO. The cytotoxic efficacy of the compounds is expressed as the mean of survival percentage ± SEM.

Compound concentration (μg/ml)	3a	3b	3c	3d	3e	3f	3g	DMSO
10000	18.5 ± 0.001	12.1 ± 0.002	18.0 ± 0.001	18.4 ± 0.002	14.1 ± 0.002	10.7 ± 0.004	12.3 ± 0.002	10.6 ± 0.018
5000	19.1 ± 0.001	12.1 ± 0.001	18.8 ± 0.001	18.5 ± 0.003	16.8 ± 0.003	11.6 ± 0.002	12.5 ± 0.001	11.2 ± 0.001
2500	19.5 ± 0.001	12.2 ± 0.001	19.0 ± 0.002	19.4 ± 0.004	17.4 ± 0.002	11.7 ± 0.009	12.7 ± 0.002	11.6 ± 0.028
1250	20.5 ± 0.004	12.7 ± 0.002	20.1 ± 0.004	19.5 ± 0.001	18.4 ± 0.003	12.6 ± 0.019	12.5 ± 0.001	14.4 ± 0.028
625	21.7 ± 0.012	12.9 ± 0.006	20.6 ± 0.003	20.0 ± 0.001	18.9 ± 0.001	15.3 ± 0.005	13.0 ± 0.003	14.4 ± 0.061
312.5	28.4 ± 0.009	13.3 ± 0.004	21.1 ± 0.004	20.5 ± 0.002	19.8 ± 0.005	77.8 ± 0.071	14.1 ± 0.002	44.4 ± 0.012
156.25	40.1 ± 0.021	16.2 ± 0.004	22.1 ± 0.011	20.5 ± 0.002	21.1± 0.012	112.0 ± 0.460	14.5 ± 0.003	103.6 ± 0.051
78.125	66.9 ± 0.018	17.3 ± 0.007	62.4 ± 0.051	31.0 ± 0.017	21.4 ± 0.073	115.9 ± 0.157	17.5 ± 0.002	109.4 ± 0.040
39.0625	73.8 ± 0.019	18.4 ± 0.006	63.0 ± 0.030	91.2 ± 0.138	45.1 ± 0.072	119.1 ± 0.122	64.1 ± 0.038	113.6 ± 0.052
19.53125	74.2 ± 0.012	23.2 ± 0.012	69.8 ± 0.027	99.2 ± 0.026	91.9 ± 0.060	144.7 ± 0.140	97.8 ± 0.053	118 ± 0.045
9.765625	87.8 ± 0.087	67.9 ± 0.048	81.6 ± 0.027	111.0 ± 0.041	114.3 ± 0.141	149.1 ± 0.106	115.9 ± 0.098	174.4 ± 0.129
4.8828125	103.5 ± 0.033	110.1 ± 0.046	91.5 ± 0.013	123.0 ± 0.026	127.5 ± 0.033	149.7 ± 0.200	131.3 ± 0.033	183.0 ± 0.078